Rising Demand In China And Asia-Pacific Will Expand Biotech Reach

Key Takeaways

• Accelerated product launches, market expansion, and manufacturing localization support strong revenue growth, cost efficiency, and operating margin improvement across core therapies.
  
• Diversified late-stage pipeline and strategic partnerships position the company for sustained innovation, financial flexibility, and long-term earnings growth.
  
• Heavy reliance on a single product, regulatory and pricing risks, ambitious but costly pipeline, and uncertain global expansion all threaten profitability, cash flow, and revenue diversification.

Catalysts

A biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets.

• Expanding access to NEFECON and VELSIPITY, the first and only approved therapies for high-burden diseases (IgAN, UC) in China and Asia-Pacific, leverages rising healthcare demand and awareness among an aging population, pointing to significant and accelerating topline revenue growth as these products penetrate new markets and patient pools.
  
• Regulatory shifts in Asia, including near-universal NRDL inclusion for NEFECON and anticipated early approval for VELSIPITY, will reduce time-to-market, allowing Everest Medicines to generate recurring revenues from new launches more quickly and rapidly expand operating leverage and gross margins.
  
• Everest's ongoing localization of manufacturing and expansion into 1,000 hospitals (80% market coverage) for NEFECON, combined with commercialization buildouts for new drugs, heightens pricing power and cost efficiencies, supporting gross margin recovery above 80% and boosting operating profit conversion.
  
• The company's robust and diversified pipeline-spanning mRNA vaccines, in vivo CAR-T, and novel autoimmune therapies-with multiple assets moving toward late-stage trials positions Everest to benefit from global moves toward precision and targeted medicines, driving long-term revenue streams and earnings growth from innovative products.
  
• Strategic partnerships, successful fund-raising, and investments (e.g., I-Mab) provide operational and financial flexibility to pursue in-licensing, shared R&D, and potential out-licensing or co-development deals, likely boosting net margins, reducing funding risk, and supporting future EPS expansion as industry appetite for biotech M&A and collaborations increases.

Everest Medicines Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Everest Medicines's revenue will grow by 50.0% annually over the next 3 years.
• Analysts assume that profit margins will increase from -17.4% today to 16.0% in 3 years time.
• Analysts expect earnings to reach CN¥923.8 million (and earnings per share of CN¥2.67) by about May 2029, up from -CN¥297.8 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as CN¥1.4 billion.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 24.8x on those 2029 earnings, up from -31.6x today. This future PE is greater than the current PE for the HK Biotechs industry at 20.4x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.29%, as per the Simply Wall St company report.

Risks

• Heavy dependence on NEFECON for near-term revenue growth raises concentration risk; any adverse regulatory, competitive, or pricing developments for this product could significantly impact overall revenues and profitability.
  
• Expansion plans for VELSIPITY and XERAVA rely on successful commercialization and broad reimbursement in China and Asia, but growing pricing pressures from NRDL inclusion, potential price cuts, and government cost containment could compress gross margins and lower net earnings over time.
  
• The company's ambitious pipeline, including mRNA-based therapies and in vivo CAR-T, will require sustained high R&D investment, and unproven late-stage clinical assets face substantial approval, adoption, and commercial execution risk, potentially increasing cash burn and future dilution risk if results disappoint.
  
• Long-term success in global expansion and out-licensing depends on stable cross-border regulatory environments; intensifying geopolitical tensions between China and the West could threaten access to key partnerships, foreign funding, trial sites, and ultimately, growth prospects beyond China, impacting revenue diversification.
  
• Despite recent capital raises, persistent non-IFRS net losses, rising G&A and selling expenses to build commercial infrastructure, and reliance on capital markets for financing suggest ongoing pressure on balance sheet strength and potential dilution, weighing on future earnings per share.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of HK$49.65 for Everest Medicines based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of HK$68.67, and the most bearish reporting a price target of just HK$25.44.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be CN¥5.8 billion, earnings will come to CN¥923.8 million, and it would be trading on a PE ratio of 24.8x, assuming you use a discount rate of 7.3%.
• Given the current share price of HK$30.94, the analyst price target of HK$49.65 is 37.7% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.